Sixty-four patients with symptomatic erosive hand osteoarthritis were randomized to receive methotrexate (MTX) 10 mg weekly (n=32) or placebo (n=32). The primary outcome was the change in pain, measured via a visual analogue scale (VAS), from baseline to 3 months. Secondary outcomes included pain at 12 months, function, and structural progression assessed using the Verbruggen-Veys (VV) and Ghent U...